The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis.
Synthetic glycopeptides have the potential to detect antibodies in multiple sclerosis (MS). In the present study, we analyzed the antibodies (IgM class, IgG class and IgG subclasses) to the synthetic glycopeptide CSF114(Glc) in the serum of 186 MS patients, 166 blood donors (BDs), 25 patients affected by meningitis/encephalitis, 41 affected by systemic lupus erythematosus (SLE) and 49 affected by rheumatoid arthritis (RA). The IgM antibody level to CSF114(Glc) was significantly increased in MS patients versus BDs (p<0.001) or versus other autoimmune diseases (SLE or RA, p<0.001). The IgG response was restricted to the subclass IgG2. IgM antibodies to CSF114(Glc) were found in 30% of relapsing/remitting MS patients and, at lower levels, in subjects affected by meningitis/encephalitis. The study of antibodies to CSF114(Glc) is a new, potential immunological marker of MS.
Lolli
Francesco
F
Dipartimento di Scienze Neurologiche e Psichiatriche, Università degli Studi di Firenze, viale Morgagni 85, I-50134 Firenze, Italy.
Mazzanti
Benedetta
B
Pazzagli
Marta
M
Peroni
Elisa
E
Alcaro
Maria Claudia
MC
Sabatino
Giuseppina
G
Lanzillo
Roberta
R
Brescia Morra
Vincenzo
V
Santoro
Lucio
L
Gasperini
Claudio
C
Galgani
Stefania
S
D'Elios
Mario Milco
MM
Zipoli
Valentina
V
Sotgiu
Stefano
S
Pugliatti
Maura
M
Rovero
Paolo
P
Chelli
Mario
M
Papini
Anna Maria
AM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000906:Antibodies / Q000097:blood* / Q000145:classification; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D005434:Flow Cytometry / Q000379:methods; D006020:Glycopeptides / Q000138:chemical synthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood* / Q000145:classification / Q000175:diagnosis / Q000276:immunology; D012372:ROC Curve; D012680:Sensitivity and Specificity
D000906:Antibodies; D006020:Glycopeptides